Kera Capital Partners, Inc. Editas Medicine, Inc. Transaction History
Kera Capital Partners, Inc.
- $483 Million
- Q2 2025
A detailed history of Kera Capital Partners, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Kera Capital Partners, Inc. holds 10,092 shares of EDIT stock, worth $23,110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,092
Previous 10,645
5.19%
Holding current value
$23,110
Previous $12.3 Million
99.82%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EDIT
# of Institutions
220Shares Held
47MCall Options Held
365KPut Options Held
354K-
Black Rock Inc. New York, NY7.78MShares$17.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$16.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$4.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$4.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$4.23 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $157M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...